ANI Pharmaceuticals Reports on NEW DAY Clinical Trial Results

An update from ANI Pharmaceuticals ( (ANIP) ) is now available.

ANI Pharmaceuticals, Inc. announced the results of the NEW DAY clinical trial for ILUVIEN®, a treatment for diabetic macular edema (DME). The trial, which was presented at the American Society of Retina Specialists Annual Scientific Meeting, showed that while ILUVIEN reduced the mean number of supplemental aflibercept injections compared to the aflibercept arm, it did not meet the primary endpoint of statistical significance. However, a post-hoc analysis indicated a statistically significant reduction in supplemental injections for a subset of patients. The trial also demonstrated non-inferiority in visual acuity and anatomic changes between the ILUVIEN and aflibercept arms. These findings suggest ILUVIEN’s potential to reduce treatment burden for DME patients, although safety concerns related to increased intraocular pressure were noted.

The most recent analyst rating on (ANIP) stock is a Buy with a $94.00 price target. To see the full list of analyst forecasts on ANI Pharmaceuticals stock, see the ANIP Stock Forecast page.

Spark’s Take on ANIP Stock

According to Spark, TipRanks’ AI Analyst, ANIP is a Outperform.

ANI Pharmaceuticals is bolstered by strong financial growth and optimistic guidance, alongside positive technical indicators suggesting upward momentum. However, its valuation is severely hampered by negative earnings, necessitating a focus on profitability improvements. Strategic corporate actions add stability, but overall, the company’s financial health and valuation challenges temper its stock attractiveness.

To see Spark’s full report on ANIP stock, click here.

More about ANI Pharmaceuticals

Average Trading Volume: 358,276

Technical Sentiment Signal: Strong Buy

Current Market Cap: $1.44B

For a thorough assessment of ANIP stock, go to TipRanks’ Stock Analysis page.